ABUS Stock Forecast: Arbutus Biopharma Corp. Price Predictions for 2026-2027
The median 12-month analyst price target for Arbutus Biopharma Corp. is $5.32. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 82 of 100 as at 21 Nov 2026 — inside the top quartile.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Arbutus Biopharma Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (99): Sales and profits are climbing, and climbing faster than before.
Revisions (20): Analysts have, on balance, been cutting their forecasts.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
ABUS stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on ABUS, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 14 Nov 2025 | Chardan Capital | Maintains | Buy | $5.00 |
| 11 Aug 2025 | Chardan Capital | Maintains | Buy | — |
| 28 Mar 2025 | Chardan Capital | Maintains | Buy | — |
| 21 Jan 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 20 Nov 2024 | Chardan Capital | Maintains | Buy | — |
| 18 Nov 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 7 Nov 2024 | Chardan Capital | Maintains | Buy | — |
| 7 Nov 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 6 Nov 2024 | Chardan Capital | Maintains | Buy | $4.00 → $4.50 |
| 5 Sept 2024 | Jefferies | Maintains | Buy | — |
| 2 Aug 2024 | JMP Securities | Maintains | Market Outperform | — |
| 7 June 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 6 June 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 5 June 2024 | Chardan Capital | Maintains | Buy | — |
| 3 May 2024 | Chardan Capital | Reiterates | Buy | — |
| 4 Apr 2024 | JMP Securities | Reiterates | Market Outperform | — |
| 1 Mar 2024 | Chardan Capital | Reiterates | Buy | — |
| 1 Mar 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 12 Sept 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 4 Aug 2023 | Chardan Capital | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for ABUS.
This page is one stock. Monday covers all of them.
ABUS appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
ABUS vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Arbutus Biopharma Corp. returned −4.3% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
ABUS analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 3.6×
- Price / sales
- 3.4×
- Price / book
- 9.3×
- EV / EBITDA
- 1.9×
Cheaper than 88% of US stocks
Cheaper than 32% of US stocks
Cheaper than 8% of US stocks
Cheaper than 90% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- 80.1%
- Net margin
- —
Higher than 99% of US stocks
- Return on equity
- 269.6%
- Return on assets
- 41.6%
- Dividend yield
- —
Higher than 99% of US stocks
Higher than 99% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Arbutus Biopharma Corp. has a market value of $616.2M and an enterprise value of $282.1M.
Revenue in the twelve months to 30 June 2026: $181.7M. The latest quarter shrank 90.6% year on year.
Net income over the same four quarters: $153.1M, a 84.2% net margin.
Free cash flow in the twelve months to 30 June 2026: −$24.6M.
Trailing P/E: 3.6×.
Arbutus Biopharma Corp. employs 19 people — $9.6M of revenue per employee.
Data provided by Twelve Data
ABUS and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at ABUS’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Arbutus Biopharma Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about ABUS
What is the ABUS stock price forecast for 2026-2027?
The median 12-month analyst price target for Arbutus Biopharma Corp. is $5.32. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is ABUS stock a buy right now?
Of the 1 analyst covering Arbutus Biopharma Corp., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Arbutus Biopharma Corp. 82 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank ABUS?
As at 21 Nov 2026, Arbutus Biopharma Corp. ranks 82 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Growth (99 of 100).
Will ABUS stock go up?
No one can know that. What the data says: the median 12-month target from 1 analyst is $5.32, and Ticker Nerd's factor model ranks Arbutus Biopharma Corp. 82 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the ABUS stock forecast for 2030?
No analyst covering Arbutus Biopharma Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ABUS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $5.32 to $5.32 over the next 12 months.
How has ABUS stock performed over the past year?
Arbutus Biopharma Corp. returned -4.3% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Arbutus Biopharma Corp. do?
Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company focused on infectious disease, with particular emphasis on chronic hepatitis B virus infection. Arbutus Biopharma Corporation is developing imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered RNA interference therapeutic, and AB-101, an oral PD-L1 inhibitor, both designed to target different aspects of HBV biology and immune response.
About Arbutus Biopharma Corp.
Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company focused on infectious disease, with particular emphasis on chronic hepatitis B virus infection. Arbutus Biopharma Corporation is developing imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered RNA interference therapeutic, and AB-101, an oral PD-L1 inhibitor, both designed to target different aspects of HBV biology and immune response. The company’s work centers on advancing virology-based therapies that may contribute to improved treatment options for patients living with chronic hepatitis B. Arbutus Biopharma Corporation operates within the broader biotechnology sector, where its current programs, proprietary drug candidates, and infectious-disease focus position it as a specialized developer of novel therapeutics.
CEO Ms. Lindsay Androski J.D., M.B.A. · 19 employees · United States · https://www.arbutusbio.com